Haemonetics Corporation (HAE) Comparison with companies in other sectors?

Haemonetics Corporation has a share price of 48.04M. You can analyze Haemonetics Corporation (HAE) competitors across different market sectors through stock heatmaps.

What are HAE's NET and operating margins?

Haemonetics Corporation (HAE) operating margin is around 0.16, and net profit margin is approximately 0.12 as of the latest reports.

In what way does HAE's earnings per share (EPS) trend reflect its financial momentum?

Haemonetics Corporation (HAE) EPS is 3.31 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Haemonetics Corporation is 22.72, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Haemonetics Corporation?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Haemonetics Corporation like P/E which is 22.08, P/B which is 3.89, and PEG which is 0.73. Compare them with sector averages to evaluate if the stock is priced fairly.

Haemonetics Corporation

HAE•NYSE

Healthcare

Medical - Instruments & Supplies

$75.20

$0.94(1.27%)

Fundamental Analysis of Haemonetics Corporation (HAE)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$3.31

P/E Ratio

22.72

ROE

0.18%

Net Margin

0.12%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.61B

Shares OutstandingTotal number of shares issued

$48.04M

Book Value/ShareNet worth per share

$19.34

Revenue/ShareAnnual revenue per share

$27.66

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$3.31

Net MarginNet income as percentage of revenue

12.32%

Operating MarginOperating income as percentage of revenue

16.30%

ROEReturn on shareholders' equity

18.41%

ROAReturn on total assets

6.84%

ROCEReturn on capital employed

11.84%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.90

Cash/ShareCash and equivalents per share

$6.24

FCF YieldFree cash flow as percentage of market cap

3.94%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for HAEFinancial Ratios Analysis details for HAE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HAESector Benchmarking details for HAE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Haemonetics Corporation Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Haemonetics Corporation. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Haemonetics Corporation's unique business strengths and challenges.

Key Financial Metrics for Haemonetics Corporation

For Haemonetics Corporation, essential financial indicators include EPS 3.31, PE 22.72, and ROE 0.18. These key ratios reveal insights into Haemonetics Corporation's profitability, valuation, and operational health. Understanding these metrics enables you to compare Haemonetics Corporation with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Haemonetics Corporation

Metrics like Net Margin 12.32% and ROA 6.84% shed light on how well Haemonetics Corporation is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Haemonetics Corporation can sustain its operations and continue growing in the future.

Valuation and Market Position of Haemonetics Corporation

Using ratios such as P/B Ratio 3.89 and PEG Ratio 0.73, investors can assess whether Haemonetics Corporation is appropriately valued based on its financials and growth potential. These figures, combined with Haemonetics Corporation's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Haemonetics Corporation

Financial health indicators, such as Debt/Equity Ratio 1.29 and Cash Flow $2.90, provide a snapshot of Haemonetics Corporation's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Haemonetics Corporation, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Haemonetics Corporation

Investing in Haemonetics Corporation based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Haemonetics Corporation focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;